• Yidu Tech annual report flagged a shift to full-year profitability in FY2026, underpinned by higher-margin delivery and tighter cost control.
• AI for Medical expanded deployments across top hospitals and public-sector platforms, with wider rollout of agent-based clinical workflow tools.
• Life sciences operations deepened work with multinational drugmakers, scaling clinical research delivery and real-world evidence programs across key disease areas.
• AI for Care extended its city-level inclusive insurance footprint, accelerated fast-claims automation, and broadened chronic disease digital therapeutics in primary care systems.
• Board proposed a final dividend of HK$ 0.04 per share, citing stronger operating quality and a solid cash position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yidu Tech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260724-12255982), on July 24, 2026, and is solely responsible for the information contained therein.